Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panther study
ISRCTN39017665Phase 3Completed
- Sponsor
- Karolinska University Hospital
- Start
- Feb 2007
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of epirubicin, cyclophosphamide, docetaxel and fluorouracil in breast cancer (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Breast cancer relapse-free survival. Started Feb 2007; status: completed.
02
Drugs
epirubicincyclophosphamidedocetaxelfluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN39017665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN39017665.